Eragidomide

SKU: orb1309843

Description

Eragidomide

Research Area

Cell Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1860875-51-9
• MW: 461.85
• Purity: 99.41%
• Formula: C₂₂H₁₈ClF₂N₃O₄
• SMILES: O=C1N(CC=2C1=CC=C(CNC(C(F)(F)C3=CC=C(Cl)C=C3)=O)C2)C4C(=O)NC(=O)CC4
• Target: Apoptosis,Ligands for E3 Ligase,Molecular Glues
• Solubility: DMSO:128.75 mg/mL (278.77 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (10.83 mM)

Bioactivity

• In Vivo:
  In NOD/SCID mice, heterogeneous responses to the Eragidomide treatment (2.5mg/kg BID for 4 weeks) were observed. Of 35 AML samples tested, 16 were highly responsive to Eragidomide with >75% reduction of AML engraftment, 10 showed moderate response between 45% and 75% reductions, and 9 showed reductions of <25%. AML is clinically characterized by the accumulation of blasts that are impaired for differentiation and maturation. Eragidomide induced myeloid differentiation of AML blasts in the Eragidomide responders.
• In Vitro:
  Eragidomide demonstrated potent antiproliferative activity in 10 of 11 cell lines (e.g. NB4, U937, KG-1, MOLM-13, HL60 cells)with much less effect on the cell viability of PBMCs and THLE-2. The antiproliferative effect of Eragidomide is associated with apoptosis induction in all tested AML cell lines except OCI-AML3.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CRBN, degradation, E3 ligase-recruiting Moiety, cereblon (CRBN) E3 ligase, Cereblon, Cereblon modulator 1, CC 90009, CC-90009, CC90009, c-myc, anti-cancer, Apoptosis, Eragidomide, Inhibitor, IKZF1, IKZF3, MolecularGlues, Molecular Glues, LigandforE3Ligase, Ligands for E3 Ligase, Ligand for E3 Ligase, inhibit, IRF4, T-lymphocytes, proteasome-mediated

Compound Identifiers

PubChem CID

118647211